Summary Highlights:
- Merck (MRK, Financial) exceeded Q1 2025 expectations with $15.5 billion in sales, despite a decline from last year.
- Keytruda sales rose by 4% reaching $7.2 billion; however, Gardasil sales fell sharply by 41%.
- Analysts predict a robust upside for Merck, with a consensus "Outperform" rating.
Merck & Co., Inc. (MRK) delivered an impressive performance in its fiscal Q1 2025, reporting better-than-expected financial results. Despite an overall 2% decline from the previous year, the company's global sales reached a significant $15.5 billion. A closer look reveals that Keytruda, a cornerstone of Merck's portfolio, is driving sales growth with a 4% increase, achieving $7.2 billion in revenue. In contrast, the Gardasil franchise experienced a notable 41% drop to $1.3 billion, primarily due to decreased demand in the Chinese market. Importantly, Merck has revised its full-year earnings outlook, factoring in a $200 million tariff impact.
Wall Street Analysts Forecast
When it comes to Merck & Co., Inc.'s (MRK, Financial) stock performance, experts remain optimistic. Utilizing one-year price targets provided by 22 analysts, the average target price is set at $110.25. The estimates range significantly, with a high of $146.00 and a low of $89.00. These projections suggest a potential upside of 40.02% from the current trading price of $78.74. For more detailed insights, please visit the Merck & Co Inc (MRK) Forecast page.
The consensus among 27 brokerage firms places Merck & Co., Inc. (MRK, Financial) in the "Outperform" category with an average recommendation rating of 2.1. This rating is on a scale where 1 indicates a "Strong Buy" and 5 signifies a "Sell", underscoring a positive market sentiment towards the stock.
According to GuruFocus estimates, the GF Value for Merck & Co., Inc. (MRK, Financial) stands at $120.94 in one year, presenting an upside of 53.59% from the current price point of $78.74. The GF Value is an estimation of the stock's fair market value, derived from historical trading multiples, past business growth patterns, and future business performance projections. More detailed information is available on the Merck & Co Inc (MRK) Summary page.
